Everything tagged "value" across research, earnings, and macro.
21 articles
Lululemon remains profitable and cash-generative, but North America softness, margin pressure, and tariff headwinds are weighing on the stock. International growth and a low earnings multiple keep the setup constructive.
Prudential plc ADR combines solid Asia-led growth with strong capital generation and a shareholder-friendly buyback plan. The stock screens as a moderate-risk Buy with a valuation that still leaves room for upside.
Blackstone’s scale in alternatives, rising perpetual capital, and AI-linked infrastructure exposure are driving durable fee growth. Valuation is rich, but the franchise still supports a Buy call.
Novo Nordisk remains a premier cardiometabolic franchise, but near-term pricing pressure and a weak 2026 outlook are tempering the story. The stock looks attractive for patient investors who can look through the reset and wait for obesity and pipeline reacceleration.
Ciena’s AI-era bandwidth demand is driving record revenue, a bigger backlog, and sharp EPS growth. The stock looks high quality but expensive, so the report lands on a Hold with upside only on pullbacks.
BeiGene has crossed from cash-burning biotech into a profitable global oncology platform, powered by BRUKINSA’s rapid growth and a strengthening balance sheet. The pipeline still matters, but the investment case now rests on commercial execution and self-funding momentum.
Medtronic is showing its strongest top-line growth in a decade, led by cardiovascular and pulsed field ablation momentum. The stock looks like a balanced Buy for moderate-risk investors, though margin pressure and debt keep the turnaround case from being pristine.
Sprinklr is a slower-growth software name, but stronger profitability, robust free cash flow, and a cash-rich balance sheet make it a selective Buy. The key debate is whether improving renewals and AI traction can offset soft customer trends and margin pressure.
Macy’s is a disciplined value turnaround with improving comps, strong cash generation, and better momentum in Bloomingdale’s and Bluemercury. Tariff pressure and a still-declining revenue base keep the setup selective, but the stock looks inexpensive versus earnings and cash flow.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator